Literature DB >> 22727293

Intrascleral fibrin glue intraocular lens fixation combined with Descemet-stripping automated endothelial keratoplasty or penetrating keratoplasty.

Rajesh Sinha1, Himanshu Shekhar, Namrata Sharma, Radhika Tandon, Jeewan S Titiyal, Rasik B Vajpayee.   

Abstract

PURPOSE: To evaluate the outcomes of intrascleral haptic fixation of an intraocular lens (IOL) with fibrin glue combined with penetrating keratoplasty (PKP) or Descemet-stripping automated endothelial keratoplasty (DSAEK) for aphakic or pseudophakic bullous keratopathy (BKP).
SETTING: Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
DESIGN: Case series.
METHODS: Eyes with BKP had combined PKP or DSAEK with fibrin glue-assisted intrascleral posterior chamber (PC) IOL fixation; PKP was performed in eyes with a corneal scar and DSAEK in eyes without a scar. The parameters evaluated were corrected distance visual acuity (CDVA), anterior segment biomicroscopy, intraocular pressure, central corneal thickness (CCT), and IOL status. Intraoperative events and postoperative complications were recorded.
RESULTS: The study evaluated 11 patients (11 eyes). Intrascleral fixation of a PC IOL with PKP or DSAEK was successfully performed in all eyes; PKP was performed in 6 eyes (54.54%) and DSAEK in 5 eyes. The mean CDVA improved from 1.95 logMAR ± 0.29 (SD) to 0.40 ± 0.16 logMAR (P<.001). The mean CCT was 0.741 ± 0.71 mm preoperatively and 0.579 ± 0.20 mm postoperatively (P<.001). There were no cases of intraoperative or postoperative IOL decentration or other complications.
CONCLUSIONS: Fibrin glue-assisted intrascleral fixation of a PC IOL combined with DSAEK or PKP was a safe, effective method to manage BKP with aphakia or malpositioned IOLs. The IOL fixation was strong enough to sustain the manipulation required for corneal procedures. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
Copyright © 2012 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727293     DOI: 10.1016/j.jcrs.2012.02.042

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  7 in total

1.  Pole to Pole Surgery in Ocular Trauma: Standardizing Surgical Steps.

Authors:  Rino Frisina; Gianluca Besozzi; Irene Gius; Angelo Greggio; Gabriella De Salvo; Alessandro Meduri
Journal:  Ophthalmol Ther       Date:  2022-09-16

2.  Endothelial keratoplasty combined with scleral fixation intraocular lens.

Authors:  Mariantonia Ferrara; Danilo Iannetta; Luca Pagano; Kunal A Gadhvi; Vito Romano
Journal:  Int J Ophthalmol       Date:  2021-01-18       Impact factor: 1.779

Review 3.  Descemet stripping automated endothelial keratoplasty.

Authors:  Namrata Sharma; Prafulla K Maharana; Shipra Singhi; Neelima Aron; Mukesh Patil
Journal:  Indian J Ophthalmol       Date:  2017-03       Impact factor: 1.848

4.  Management of pseudophakic bullous keratopathy with ultrathin Descemet stripping automated endothelial keratoplasty and modified Yamanes' technique of scleral fixation.

Authors:  Jai Kelkar; Aditya Kelkar; Yogesh Chougule
Journal:  Indian J Ophthalmol       Date:  2020-01       Impact factor: 1.848

5.  Surgical outcomes of concomitantly performed penetrating keratoplasty with intrascleral haptic fixation.

Authors:  Rinky Agarwal; Saumya Yadav; Prafulla K Maharana; Rahul K Bafna; Chetan Shakarwal; Namrata Sharma
Journal:  Indian J Ophthalmol       Date:  2022-01       Impact factor: 1.848

Review 6.  Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive-a Laboratory and Clinical Perspective.

Authors:  William D Spotnitz
Journal:  ISRN Surg       Date:  2014-03-04

7.  Repeat keratoplasty in failed Descemet stripping automated endothelial keratoplasty.

Authors:  Manpreet Kaur; Jeewan S Titiyal; Meghal Gagrani; Farin Shaikh; Tushar Agarwal; Rajesh Sinha; Namrata Sharma
Journal:  Indian J Ophthalmol       Date:  2019-10       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.